You are here: » Statin use, HMGCR expression, and breast cancer survival ...

Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Standard

Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. / Bjarnadottir, Olöf; Feldt, Maria; Inasu, Maria; Bendahl, Pär Ola; Elebro, Karin; Kimbung, Siker; Borgquist, Signe.

In: Scientific Reports, Vol. 10, No. 1, 558, 2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Harvard

Bjarnadottir, O, Feldt, M, Inasu, M, Bendahl, PO, Elebro, K, Kimbung, S & Borgquist, S 2020, 'Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study', Scientific Reports, vol. 10, no. 1, 558. https://doi.org/10.1038/s41598-019-57323-9

APA

Bjarnadottir, O., Feldt, M., Inasu, M., Bendahl, P. O., Elebro, K., Kimbung, S., & Borgquist, S. (2020). Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. Scientific Reports, 10(1), [558]. https://doi.org/10.1038/s41598-019-57323-9

CBE

Bjarnadottir O, Feldt M, Inasu M, Bendahl PO, Elebro K, Kimbung S, Borgquist S. 2020. Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. Scientific Reports. 10(1):Article 558. https://doi.org/10.1038/s41598-019-57323-9

MLA

Bjarnadottir, Olöf et al. "Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study". Scientific Reports. 2020. 10(1). https://doi.org/10.1038/s41598-019-57323-9

Vancouver

Bjarnadottir O, Feldt M, Inasu M, Bendahl PO, Elebro K, Kimbung S et al. Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. Scientific Reports. 2020;10(1). 558. https://doi.org/10.1038/s41598-019-57323-9

Author

Bjarnadottir, Olöf ; Feldt, Maria ; Inasu, Maria ; Bendahl, Pär Ola ; Elebro, Karin ; Kimbung, Siker ; Borgquist, Signe. / Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. In: Scientific Reports. 2020 ; Vol. 10, No. 1.

Bibtex

@article{5d58c2a7fce14291865fbd0593fb1520,
title = "Statin use, HMGCR expression, and breast cancer survival – The Malm{\"o} Diet and Cancer Study",
abstract = "Statins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody validation was performed for four different HMGCR antibodies. Tumor expression of HMGCR (#AMAb90619, CL0260, Atlas Antibodies, Stockholm, Sweden) was evaluated in the Malm{\"o} Diet and Cancer Study breast cancer cohort. Statin use and cause of death data were retrieved from the Swedish Prescribed Drug Register and Swedish Death Registry, respectively. Breast cancer-specific mortality (BCM) according to statin use and HMGCR expression were analyzed using Cox regression models. Three-hundred-twelve of 910 breast cancer patients were prescribed statins; 74 patients before and 238 after their breast cancer diagnosis. HMGCR expression was assessable for 656 patients; 119 showed negative, 354 weak, and 184 moderate/strong expressions. HMGCR moderate/strong expression was associated with prognostically adverse tumor characteristics as higher histological grade, high Ki67, and ER negativity. HMGCR expression was not associated with BCM. Neither was statin use associated with BCM in our study. Among breast cancer patients on statins, no or weak HMGCR expression predicted favorable clinical outcome. These suggested associations need further testing in larger cohorts.",
author = "Ol{\"o}f Bjarnadottir and Maria Feldt and Maria Inasu and Bendahl, {P{\"a}r Ola} and Karin Elebro and Siker Kimbung and Signe Borgquist",
year = "2020",
doi = "10.1038/s41598-019-57323-9",
language = "English",
volume = "10",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study

AU - Bjarnadottir, Olöf

AU - Feldt, Maria

AU - Inasu, Maria

AU - Bendahl, Pär Ola

AU - Elebro, Karin

AU - Kimbung, Siker

AU - Borgquist, Signe

PY - 2020

Y1 - 2020

N2 - Statins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody validation was performed for four different HMGCR antibodies. Tumor expression of HMGCR (#AMAb90619, CL0260, Atlas Antibodies, Stockholm, Sweden) was evaluated in the Malmö Diet and Cancer Study breast cancer cohort. Statin use and cause of death data were retrieved from the Swedish Prescribed Drug Register and Swedish Death Registry, respectively. Breast cancer-specific mortality (BCM) according to statin use and HMGCR expression were analyzed using Cox regression models. Three-hundred-twelve of 910 breast cancer patients were prescribed statins; 74 patients before and 238 after their breast cancer diagnosis. HMGCR expression was assessable for 656 patients; 119 showed negative, 354 weak, and 184 moderate/strong expressions. HMGCR moderate/strong expression was associated with prognostically adverse tumor characteristics as higher histological grade, high Ki67, and ER negativity. HMGCR expression was not associated with BCM. Neither was statin use associated with BCM in our study. Among breast cancer patients on statins, no or weak HMGCR expression predicted favorable clinical outcome. These suggested associations need further testing in larger cohorts.

AB - Statins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody validation was performed for four different HMGCR antibodies. Tumor expression of HMGCR (#AMAb90619, CL0260, Atlas Antibodies, Stockholm, Sweden) was evaluated in the Malmö Diet and Cancer Study breast cancer cohort. Statin use and cause of death data were retrieved from the Swedish Prescribed Drug Register and Swedish Death Registry, respectively. Breast cancer-specific mortality (BCM) according to statin use and HMGCR expression were analyzed using Cox regression models. Three-hundred-twelve of 910 breast cancer patients were prescribed statins; 74 patients before and 238 after their breast cancer diagnosis. HMGCR expression was assessable for 656 patients; 119 showed negative, 354 weak, and 184 moderate/strong expressions. HMGCR moderate/strong expression was associated with prognostically adverse tumor characteristics as higher histological grade, high Ki67, and ER negativity. HMGCR expression was not associated with BCM. Neither was statin use associated with BCM in our study. Among breast cancer patients on statins, no or weak HMGCR expression predicted favorable clinical outcome. These suggested associations need further testing in larger cohorts.

UR - http://www.scopus.com/inward/record.url?scp=85077978402&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-57323-9

DO - 10.1038/s41598-019-57323-9

M3 - Journal article

C2 - 31953433

AN - SCOPUS:85077978402

VL - 10

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 558

ER -